Cosentyx List Price and Annual Costs
Cosentyx (secukinumab), used for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other conditions, has a U.S. wholesale acquisition cost (WAC) of about $6,485 per 300 mg dose (two 150 mg pens or prefilled syringes).[1] For typical maintenance dosing—monthly 300 mg injections after initial loading—this equates to roughly $77,800 annually before discounts or insurance.[2]
How Cosentyx Compares to Other IL-17 Inhibitors
| Drug | Indication Overlap | Monthly WAC (300 mg equiv.) | Annual WAC Estimate |
|------|---------------------|-----------------------------|---------------------|
| Cosentyx (secukinumab) | PsO, PsA, AS | $6,485 | $77,800 |
| Taltz (ixekizumab) | PsO, PsA, AS | $6,056 | $72,700 [1][3] |
| Cyltezo (biosimilar adalimumab) | PsO, PsA (not AS primary) | $3,000–$4,000 (per 40 mg) | $36,000–$48,000 [4] |
Taltz costs 5-10% less per dose but similar annually due to comparable regimens. Biosimilars like Cyltezo undercut originators by 50-70%.[1]
Comparison to TNF Inhibitors
TNF blockers like Humira (adalimumab) list at $6,000+ monthly but face heavy biosimilar competition, dropping effective prices to $2,000–$4,000 annually with insurance or patient assistance.[3][5] Newer options like Simponi Aria (golimumab IV) run $5,000–$6,000 per infusion (biweekly to monthly), totaling $60,000–$72,000 yearly.[2]
| Drug | Annual WAC (typical dose) | Biosimilar Availability |
|------|---------------------------|-------------------------|
| Humira | $80,000+ | Yes (2023 entry) [5] |
| Enbrel (etanercept) | $60,000–$70,000 | Partial [1] |
| Stelara (ustekinumab) | $50,000–$60,000 | Biosimilars 2025 [6] |
Cosentyx often costs more upfront than TNF biosimilars but less than originator biologics.
Real-World Costs After Discounts and Insurance
List prices overstate patient costs. Net prices after rebates average 40-50% off WAC for Cosentyx ($40,000–$50,000 annually).[7] With commercial insurance, copays range $0–$100/month via manufacturer copay cards (up to $15,000/year assistance).[2] Medicare patients pay 20% coinsurance (~$15,000/year pre-cap) but qualify for Extra Help reducing it further.[8] Uninsured access via Novartis patient assistance covers full cost for incomes under 500% FPL.[2]
Factors Driving Price Differences
Biosimilars erode costs fastest for TNFs (e.g., Humira down 80% net since 2023).[5] Cosentyx patent expires 2031–2034 (U.S. method-of-use to 2034), delaying generics.[9] DrugPatentWatch.com tracks 20+ patents; challenges from Alvotech could accelerate entry. IL-23 inhibitors like Tremfya ($70,000/year) compete on efficacy, not price.[3]
When Cheaper Alternatives Make Sense
Switch to biosimilars if tolerated—savings up to $40,000/year vs. Cosentyx.[4] Oral options like Otezla (apremilast) cost $50,000–$60,000 annually but avoid injections.[10] Efficacy varies: Cosentyx clears psoriasis in 80% at week 12 vs. 70% for some TNFs.[11]
Sources
[1]: DrugPatentWatch.com
[2]: Novartis pricing (2024)
[3]: IQVIA data
[4]: FDA biosimilar approvals
[5]: HHS ASPE report (2024)
[6]: Stelara patent settlement
[7]: SSR Health net pricing
[8]: CMS Medicare Part D
[9]: DrugPatentWatch.com
[10]: Amgen Otezla
[11]: NEJM head-to-head trials